Targeting fibroblast activation protein-α to treat renal fibrosis - PubMed
5 hours ago
- #FAP Targeting
- #CAR T-cell Immunotherapy
- #Renal Fibrosis
- Targeting fibroblast activation protein-α (FAP) to treat renal fibrosis.
- The study involves chimeric antigen receptor (CAR) T-cell immunotherapy.
- Ethics approval was obtained from Changzhou Seventh People’s Hospital on November 8, 2021, with ethical number LC2021.
- Animal ethics approval was obtained from Nanfang Hospital Animal Ethic Committee on July 11, 2020, with ethical number NFYY-2020-0719.
- Lei Huang is the founder and director of Zeal BioScience Group Limited.
- Several references discuss mechanisms and therapies for renal fibrosis, including Wnt signaling and angiotensin-converting enzyme inhibition.